US FDA Launches Quality Maturity Pilot Program That Rewards High-Performing Manufacturers
Executive Summary
High ratings on factors like quality culture could yield post-approval change flexibility for participating drug product and API manufacturing facilities.
You may also be interested in...
What Carrots Will US FDA Offer For Quality Management Maturity Participation?
Sector-specific incentives may be necessary, but the FDA has not made a final decision.
US FDA Makes Case For Quality Management Maturity Ratings
High ratings could strengthen company financial performance, agency suggests. But stakeholders would need to understand the difference between site QMM and product quality for the incentives to work properly. More details to follow in upcoming workshop.
US FDA’s Drug Shortage Program On ‘Site Engagement’ To Be Nixed In GDUFA III
Generics industry and FDA also debated inspection policies in lieu of travel and safety restrictions mandated by the pandemic.